MD Medical Group Opens New Clinic in Volgograd
|Download file (296 K)|
MD Medical Group Investments Plc (“MD Medical Group”, “MDMG” or the “Company” – LSE: MDMG), the leading Russian private healthcare provider, announces that it has opened its first out-patient clinic in Volgograd.
The new clinic Mother&Child Volgograd has an area of approximately 380 sq. m. It offers a wide range of the Group’s core services for women such as IVF, ultrasound, minor gynaecological operations in the day-patient centre, OBGYN, and foetal medicine. In addition, the clinic offers services in endocrinology, urology, andrology, ophthalmology, etc.
The Group’s total investment in the project amounted to approximately 40 million roubles.
The new clinic is able to carry out up to 500 IVF cycles, including under the Mandatory Health Insurance (MHI) programme, and it can accommodate up to 20,000 doctor’s appointments, and up to 1,000 minor gynaecological operations per year.
Mother&Child Volgograd has been created in line with MD Medical Group’s customary high standards of medical care and is fitted out with world-class equipment.
Mark Kurtser, CEO of MD Medical Group, said:
“We have continued the strategic expansion of our footprint in the regions of Russia which are the most attractive for our business. By entering Volgograd, we make it possible for not only the residents of this million-strong city, but also residents of the neighbouring southern regions of the country, to get access to our hi-tech medical services.“The clinic in Volgograd is an excellent example of our commitment to providing our patients with a wide scope of services including our traditional focus on women’s and children’s healthcare. The clinic will not only offer our core services such as IVF under the MHI programme, but also medical services for all family members, including endocrinology, urology, andrology, ophthalmology, among others.“Today, we are present in more Russian regions than other private healthcare player and offer services to patients in 11 out of 15 cities in Russia with a population of more than a million. Thanks to our ongoing regional expansion, our team has gained valuable experience in efficiently launching new facilities, positioning us well to realise new value-enhancing projects as we continue to expand our business.”
For further information please contact:
MD Medical Group Investments Plc
Tel: +7 495 331 4120
Tom Blackwell: +7 919 102 9064
Sergii Pershyn: +1 929 855 8188
About MD Medical Group
MD Medical Group is a leading provider in the highly attractive Russian private healthcare service market. The company manages 38 modern healthcare facilities, including 5 hospitals and 33 outpatient clinics in Moscow and the Moscow Region, St. Petersburg, Ufa, Perm, Samara and the Samara Region, Irkutsk, Novosibirsk, Irkutsk, Yaroslavl, Ryazan, Kostroma, Novokuznetsk, Krasnoyarsk, Omsk, Barnaul, Vladimir, Tyumen, Voronezh, Nizhny Novgorod, and Volgograd.
The Company’s shares have been listed on the London Stock Exchange (LSE ticker “MDMG”) in the form of Global Depositary Receipts (GDRs) since 12 October 2012.
This press release contains forward looking statements, which are based on the Company’s current expectations and assumptions and may involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. The forward looking statements contained in this press release are based on past trends or activities and should not be taken that such trends or activities will continue in the future. It is believed that the expectations reflected in these statements are reasonable, but they may be affected by a number of variables which could cause actual results or trends to differ materially, including, but not limited to: conditions in the market, market position of the Company, earnings, financial position, cash flows, return on capital and operating margins, anticipated investments and economic conditions; the Company’s ability to obtain capital/additional finance; a reduction in demand by customers; an increase in competition; an unexpected decline in revenue or profitability; legislative, fiscal and regulatory developments, including, but not limited to, changes in environmental and health and safety regulations; exchange rate fluctuations; retention of senior management; the maintenance of labour relations; fluctuations in the cost of input costs; and operating and financial restrictions as a result of financing arrangements.
No statement in this press release is intended to constitute a profit forecast, nor should any statements be interpreted to mean that earnings or earnings per share will necessarily be greater or lesser than those for the relevant preceding financial periods for the Company. Each forward looking statement relates only as of the date of the particular statement.
2018 2017 2016 2015 2014 2013 2012